Another promising approach for hard-to-treat blood cancers

For patients with some hard-to-treat blood cancers, a simple “off-the-shelf” immunotherapy is achieving promising results. A clinical trial of the developmental drug Glofitamab has shown it can produce a durable “complete response”—meaning the cancer became undetectable—in patients with relapsed or treatment resistant B-cell lymphomas. One option for these patients is CAR T-cell therapy—also an immunotherapy but one which involves collecting […]

Read more

Another promising approach for hard-to-treat blood cancers

For patients with some hard-to-treat blood cancers, a simple “off-the-shelf” immunotherapy is achieving promising results. A clinical trial of the developmental drug Glofitamab has shown it can produce a durable “complete response”—meaning the cancer became undetectable—in patients with relapsed or treatment resistant B-cell lymphomas. One option for these patients is CAR T-cell therapy—also an immunotherapy but one which involves collecting […]

Read more

Sutimlimab shows promise for hard-to-treat, rare blood disorder

In a first-in-human clinical trial reported today in Blood, the investigational drug sutimlimab appeared to be effective in treating cold agglutinin disease, a rare chronic blood disorder for which there are currently no approved treatments. Cold agglutinin disease is caused by a malfunction in the immune system that causes antibodies—components of the immune system that are produced in the blood […]

Read more